# Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency

> **NCT04892693** · PHASE2 · RECRUITING · sponsor: **Seoul National University Hospital** · enrollment: 70 (estimated)

## Conditions studied

- Advanced Breast Cancer

## Interventions

- **DRUG:** Talazoparib Oral Capsule

## Key facts

- **NCT ID:** NCT04892693
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-05-25
- **Primary completion:** 2027-05-31
- **Final completion:** 2027-05-31
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2025-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04892693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04892693, "Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT04892693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*